Prana launches Phase II study of Alzheimer's drug

03/6/2012 | ProactiveInvestors.co.au (Australia)

Prana Biotechnology has started with the first patient in a 12-month Phase II trial that will monitor levels of amyloid in the brain and assess cognitive and functional abilities in participants treated with PBT2, the company's investigational drug for Alzheimer's disease. Study participants will undergo PiB-PET imaging prior to treatment to determine starting amyloid levels.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA